Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study
Authorized Users Only
2015
Authors
Kovač, MirjanaKovac, Zeljko
Tomasević, Zorica
Vucicević, Slavko
Đorđević, Valentina
Pruner, Iva
Radojković, Dragica
Article (Published version)
Metadata
Show full item recordAbstract
Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer patients whose treatment included adjuvant tamoxifen. Methods: The prospective, single center, case control study included 150 breast cancer women, 50 whom developed venous thrombosis during adjuvant tamoxifen and 100 whom did not have thrombosis, as a control group. Patient-related risk factors such as: age, body mass index, previous VTE, varicose veins, concomitant diseases, the presence of prothrombotic mutations (FV Leiden, FII G20210A) and FVIII activity were evaluated in both groups. Results: In respect of prothrombotic mutations, the FV Leiden mutation was present in a higher nu...mber of women from the VTE group (10/50 vs 7/100; P = 0.020). Additionally, FVIII activity was significantly higher in the VTE group; median (IQR), of 1.79 (0.69) vs 1.45 (0.55); P lt 0.001 and more women in this group (24/50 vs 34/100) had increased FVIII activity; P = 0.020. In those women with FVIII gt 1.5 IU/ml, who were carriers of prothrombotic mutations, an OR of 3.76 (CI 95% 1.276-11.096; P = 0.016) was obtained for VTE. Conclusion: The results of our study showed that the factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen.
Keywords:
Venous thromboembolism / Tamoxifen / FV Leiden / Factor VIII / Breast cancerSource:
European Journal of Internal Medicine, 2015, 26, 1, 63-67Publisher:
- Elsevier, Amsterdam
Funding / projects:
- Complex diseases as a model system for phenotype modulation- structural and functional analysis of molecular biomarkers (RS-MESTD-Basic Research (BR or ON)-173008)
DOI: 10.1016/j.ejim.2014.12.015
ISSN: 0953-6205
PubMed: 25592075
WoS: 000348503100012
Scopus: 2-s2.0-84921550543
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Kovač, Mirjana AU - Kovac, Zeljko AU - Tomasević, Zorica AU - Vucicević, Slavko AU - Đorđević, Valentina AU - Pruner, Iva AU - Radojković, Dragica PY - 2015 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/852 AB - Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer patients whose treatment included adjuvant tamoxifen. Methods: The prospective, single center, case control study included 150 breast cancer women, 50 whom developed venous thrombosis during adjuvant tamoxifen and 100 whom did not have thrombosis, as a control group. Patient-related risk factors such as: age, body mass index, previous VTE, varicose veins, concomitant diseases, the presence of prothrombotic mutations (FV Leiden, FII G20210A) and FVIII activity were evaluated in both groups. Results: In respect of prothrombotic mutations, the FV Leiden mutation was present in a higher number of women from the VTE group (10/50 vs 7/100; P = 0.020). Additionally, FVIII activity was significantly higher in the VTE group; median (IQR), of 1.79 (0.69) vs 1.45 (0.55); P lt 0.001 and more women in this group (24/50 vs 34/100) had increased FVIII activity; P = 0.020. In those women with FVIII gt 1.5 IU/ml, who were carriers of prothrombotic mutations, an OR of 3.76 (CI 95% 1.276-11.096; P = 0.016) was obtained for VTE. Conclusion: The results of our study showed that the factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen. PB - Elsevier, Amsterdam T2 - European Journal of Internal Medicine T1 - Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study EP - 67 IS - 1 SP - 63 VL - 26 DO - 10.1016/j.ejim.2014.12.015 ER -
@article{ author = "Kovač, Mirjana and Kovac, Zeljko and Tomasević, Zorica and Vucicević, Slavko and Đorđević, Valentina and Pruner, Iva and Radojković, Dragica", year = "2015", abstract = "Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer patients whose treatment included adjuvant tamoxifen. Methods: The prospective, single center, case control study included 150 breast cancer women, 50 whom developed venous thrombosis during adjuvant tamoxifen and 100 whom did not have thrombosis, as a control group. Patient-related risk factors such as: age, body mass index, previous VTE, varicose veins, concomitant diseases, the presence of prothrombotic mutations (FV Leiden, FII G20210A) and FVIII activity were evaluated in both groups. Results: In respect of prothrombotic mutations, the FV Leiden mutation was present in a higher number of women from the VTE group (10/50 vs 7/100; P = 0.020). Additionally, FVIII activity was significantly higher in the VTE group; median (IQR), of 1.79 (0.69) vs 1.45 (0.55); P lt 0.001 and more women in this group (24/50 vs 34/100) had increased FVIII activity; P = 0.020. In those women with FVIII gt 1.5 IU/ml, who were carriers of prothrombotic mutations, an OR of 3.76 (CI 95% 1.276-11.096; P = 0.016) was obtained for VTE. Conclusion: The results of our study showed that the factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen.", publisher = "Elsevier, Amsterdam", journal = "European Journal of Internal Medicine", title = "Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study", pages = "67-63", number = "1", volume = "26", doi = "10.1016/j.ejim.2014.12.015" }
Kovač, M., Kovac, Z., Tomasević, Z., Vucicević, S., Đorđević, V., Pruner, I.,& Radojković, D.. (2015). Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study. in European Journal of Internal Medicine Elsevier, Amsterdam., 26(1), 63-67. https://doi.org/10.1016/j.ejim.2014.12.015
Kovač M, Kovac Z, Tomasević Z, Vucicević S, Đorđević V, Pruner I, Radojković D. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study. in European Journal of Internal Medicine. 2015;26(1):63-67. doi:10.1016/j.ejim.2014.12.015 .
Kovač, Mirjana, Kovac, Zeljko, Tomasević, Zorica, Vucicević, Slavko, Đorđević, Valentina, Pruner, Iva, Radojković, Dragica, "Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study" in European Journal of Internal Medicine, 26, no. 1 (2015):63-67, https://doi.org/10.1016/j.ejim.2014.12.015 . .